Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact
Open Access
- 1 April 2021
- journal article
- editorial
- Published by The Korean Association for the Study of the Liver in Clinical and Molecular Hepatology
- Vol. 27 (2), 273-277
- https://doi.org/10.3350/cmh.2021.0019
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Management of chronic hepatitis B patients in immunetolerant phase: what latest guidelines recommendClinical and Molecular Hepatology, 2018
- Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis BJournal of Hepatology, 2018
- Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidanceJournal of Hepatology, 2018
- High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis BGut, 2017
- Nucleos(t)ide Analogue Treatment for Patients With Hepatitis B Virus (HBV) e Antigen–Positive Chronic HBV Genotype C Infection: A Nationwide, Multicenter, Retrospective StudyThe Journal of Infectious Diseases, 2017
- EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infectionJournal of Hepatology, 2017
- Adaptive immunity in HBV infectionJournal of Hepatology, 2016
- Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 updateHepatology International, 2015
- Effects of Tenofovir Disoproxil Fumarate in Hepatitis B e Antigen-Positive Patients With Normal Levels of Alanine Aminotransferase and High Levels of Hepatitis B Virus DNAGastroenterology, 2014
- Accuracy of Risk Scores for Patients With Chronic Hepatitis B Receiving Entecavir TreatmentGastroenterology, 2013